| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comment on “Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms”
|
McFarland, Daniel C.
|
|
|
145 |
C |
p. 205-207
|
artikel
|
| 2 |
A cross-modal 3D deep learning for accurate lymph node metastasis prediction in clinical stage T1 lung adenocarcinoma
|
Zhao, Xingyu
|
|
|
145 |
C |
p. 10-17
|
artikel
|
| 3 |
A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
|
Sereno, María
|
|
|
145 |
C |
p. 213-215
|
artikel
|
| 4 |
A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non–small cell lung cancer
|
Deng, Jiajun
|
|
|
145 |
C |
p. 33-39
|
artikel
|
| 5 |
Analysis of MET kinase domain rearrangement in NSCLC
|
Zhuo, Minglei
|
|
|
145 |
C |
p. 140-143
|
artikel
|
| 6 |
A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib
|
Zhong, Jiang-Ming
|
|
|
145 |
C |
p. 211-212
|
artikel
|
| 7 |
A reply to “A comment on “Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience”
|
Drevet, Gabrielle
|
|
|
145 |
C |
p. 222-224
|
artikel
|
| 8 |
A reply to “Immune related adverse events and response to immunotherapy: focus on corticosteroids.”
|
Baldini, Editta
|
|
|
145 |
C |
p. 226
|
artikel
|
| 9 |
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment
|
Beagan, Jamie J.
|
|
|
145 |
C |
p. 173-180
|
artikel
|
| 10 |
Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233–240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004
|
Crengle, Sue
|
|
|
145 |
C |
p. 219-220
|
artikel
|
| 11 |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Lin, Yen-Ting
|
|
|
145 |
C |
p. 1-9
|
artikel
|
| 12 |
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors
|
Cheng, Ying
|
|
|
145 |
C |
p. 63-70
|
artikel
|
| 13 |
Contents
|
|
|
|
145 |
C |
p. v-vii
|
artikel
|
| 14 |
Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma
|
Tamura, Nobumasa
|
|
|
145 |
C |
p. 152-157
|
artikel
|
| 15 |
Corrigendum to “167 - An audit of the management of mesothelioma in Southern England” [Lung Cancer 139 (Suppl. 1) (January 2020) S72–S73]
|
Rudd, P.
|
|
|
145 |
C |
p. 228
|
artikel
|
| 16 |
Corrigendum to “141 – Peptide receptor radionuclide therapy for metastatic bronchopulmonary carcinoid tumours: A single ENETS Centre of Excellence experience” [Lung Cancer 127 (Suppl. 1) (January) (2019) S59]
|
Evans, J.
|
|
|
145 |
C |
p. 227
|
artikel
|
| 17 |
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
|
Dall’Olio, Filippo G.
|
|
|
145 |
C |
p. 95-104
|
artikel
|
| 18 |
Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification
|
Isaka, Tetsuya
|
|
|
145 |
C |
p. 111-118
|
artikel
|
| 19 |
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial
|
Quist, Morten
|
|
|
145 |
C |
p. 76-82
|
artikel
|
| 20 |
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
|
Yang, Guangjian
|
|
|
145 |
C |
p. 186-194
|
artikel
|
| 21 |
EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma
|
Jiang, Hui
|
|
|
145 |
C |
p. 216-218
|
artikel
|
| 22 |
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models
|
Martins-Filho, Sebastiao N.
|
|
|
145 |
C |
p. 144-151
|
artikel
|
| 23 |
High risk, same reward?
|
Chen, Hanbo
|
|
|
145 |
C |
p. 221
|
artikel
|
| 24 |
Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma
|
Arjonen, Antti
|
|
|
145 |
C |
p. 27-32
|
artikel
|
| 25 |
Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
|
Di Noia, Vincenzo
|
|
|
145 |
C |
p. 208-210
|
artikel
|
| 26 |
Immune related adverse events and response to immunotherapy: Focus on corticosteroids
|
Indini, Alice
|
|
|
145 |
C |
p. 225
|
artikel
|
| 27 |
Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience
|
Rossi, David
|
|
|
145 |
C |
p. 83-84
|
artikel
|
| 28 |
Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms
|
Andersen, B.L.
|
|
|
145 |
C |
p. 195-204
|
artikel
|
| 29 |
Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV
|
Gounant, Valérie
|
|
|
145 |
C |
p. 71-75
|
artikel
|
| 30 |
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer
|
Solomon, Benjamin J.
|
|
|
145 |
C |
p. 167-172
|
artikel
|
| 31 |
Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma
|
Yotsukura, Masaya
|
|
|
145 |
C |
p. 158-166
|
artikel
|
| 32 |
Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses
|
Ishihara, Shunta
|
|
|
145 |
C |
p. 40-47
|
artikel
|
| 33 |
Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy
|
Friedes, Cole
|
|
|
145 |
C |
p. 119-125
|
artikel
|
| 34 |
Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome
|
Thomas, Richard
|
|
|
145 |
C |
p. 132-139
|
artikel
|
| 35 |
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France)
|
Hofman, Véronique
|
|
|
145 |
C |
p. 58-62
|
artikel
|
| 36 |
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
|
Pertejo-Fernandez, Ana
|
|
|
145 |
C |
p. 181-185
|
artikel
|
| 37 |
Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients
|
Kobayashi, Aki K.
|
|
|
145 |
C |
p. 105-110
|
artikel
|
| 38 |
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study
|
Morgensztern, Daniel
|
|
|
145 |
C |
p. 126-131
|
artikel
|
| 39 |
Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer
|
Chen, Vincent
|
|
|
145 |
C |
p. 48-57
|
artikel
|
| 40 |
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
|
Takada, Kazuki
|
|
|
145 |
C |
p. 18-26
|
artikel
|
| 41 |
Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence
|
Miyanaga, Akihiko
|
|
|
145 |
C |
p. 85-94
|
artikel
|
Tijdschrift beschrijving